Quanterix (QTRX) closed at $2.07 on November 18, 2026, down 27.6% from the previous close, on volume of 3,346,007 shares (30-day average 474,542).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | 4 Leg Call Combo Calendar with Ratio | 19-Feb-27 5|19-Feb-27 2.5|21-May-27 5|21-May-27 2.5[1.5x] C | 225 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
Quanterix Names Jim Gute Interim CEO After Cunningham Resigns
TipRanks (Wed, 18-Nov 9:21 AM ET)
Quanterix appoints Jim Gute as interim CEO as Everett Cunningham steps down
Seeking Alpha News (Wed, 18-Nov 8:32 AM ET)
Seeking Alpha News (Wed, 18-Nov 8:09 AM ET)
Quanterix Announces Leadership Transition Plan
Business Wire (Wed, 18-Nov 8:03 AM ET)
Diagnostic stocks safe from proposed crackdown on Medicare fraud
Seeking Alpha News (Tue, 17-Nov 10:41 AM ET)
Business Wire (Mon, 16-Nov 1:30 PM ET)
Quanterix Earnings Call Signals Recovery Amid Execution Risks
TipRanks (Sat, 14-Nov 10:39 PM ET)
Quanterix Releases Financial Results for the Third Quarter of 2026
Business Wire (Mon, 9-Nov 8:00 AM ET)
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026
Business Wire (Wed, 28-Oct 4:30 PM ET)
Market Chameleon (Wed, 7-Oct 7:09 AM ET)
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Quanterix trades on the NASDAQ stock market under the symbol QTRX.
As of November 19, 2026, QTRX stock price declined to $1.80 with 931,400 million shares trading.
QTRX has a beta of 0.61, meaning it tends to be less sensitive to market movements. QTRX has a correlation of 0.01 to the broad based SPY ETF.
QTRX has a market cap of $85.46 million. This is considered a Micro Cap stock.
Last quarter Quanterix reported $35 million in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.08.
In the last 3 years, QTRX traded as high as $29.70 and as low as $1.77.
The top ETF exchange traded funds that QTRX belongs to (by Net Assets): IWM, VTI, VXF, IWN, IBB.
QTRX has underperformed the market in the last year with a price return of -68.0% while the SPY ETF gained +11.5%. QTRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.8% and -40.8%, respectively, while the SPY returned -4.8% and -5.0%, respectively.
QTRX support price is $1.96 and resistance is $2.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTRX shares will trade within this expected range on the day.